JP2008524328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008524328A5 JP2008524328A5 JP2007548300A JP2007548300A JP2008524328A5 JP 2008524328 A5 JP2008524328 A5 JP 2008524328A5 JP 2007548300 A JP2007548300 A JP 2007548300A JP 2007548300 A JP2007548300 A JP 2007548300A JP 2008524328 A5 JP2008524328 A5 JP 2008524328A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- branched
- linear
- group
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- -1 substituted Chemical class 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 4
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims 4
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims 4
- 102000034337 acetylcholine receptors Human genes 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000003551 muscarinic effect Effects 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 125000001118 alkylidene group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 230000009286 beneficial effect Effects 0.000 claims 3
- 230000004044 response Effects 0.000 claims 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 230000008485 antagonism Effects 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000004406 elevated intraocular pressure Effects 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000034972 Sudden Infant Death Diseases 0.000 claims 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 125000005819 alkenylalkoxy group Chemical group 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000472 muscarinic agonist Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 230000008403 visual deficit Effects 0.000 claims 1
- 0 *C(C1)C2NC1CC(*)C2 Chemical compound *C(C1)C2NC1CC(*)C2 0.000 description 6
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/019,556 US7550459B2 (en) | 2001-12-28 | 2004-12-21 | Tetrahydroquinoline analogues as muscarinic agonists |
| US11/019,556 | 2004-12-21 | ||
| PCT/US2005/045313 WO2006068904A1 (en) | 2004-12-21 | 2005-12-15 | Tetrahydroquinoline analogues as muscarinic agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008524328A JP2008524328A (ja) | 2008-07-10 |
| JP2008524328A5 true JP2008524328A5 (enExample) | 2009-02-05 |
| JP5114208B2 JP5114208B2 (ja) | 2013-01-09 |
Family
ID=36123554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548300A Expired - Fee Related JP5114208B2 (ja) | 2004-12-21 | 2005-12-15 | ムスカリン作動薬としてのテトラヒドロキノリン類似体 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7550459B2 (enExample) |
| EP (1) | EP1828176A1 (enExample) |
| JP (1) | JP5114208B2 (enExample) |
| KR (2) | KR20130095846A (enExample) |
| CN (2) | CN102796095B (enExample) |
| AR (1) | AR052343A1 (enExample) |
| AU (1) | AU2005319426B2 (enExample) |
| BR (1) | BRPI0517485A (enExample) |
| CA (1) | CA2591766C (enExample) |
| IL (2) | IL184065A (enExample) |
| MX (1) | MX2007007588A (enExample) |
| NO (1) | NO20073183L (enExample) |
| NZ (1) | NZ555994A (enExample) |
| RU (1) | RU2434865C2 (enExample) |
| TW (2) | TW201414731A (enExample) |
| WO (1) | WO2006068904A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550459B2 (en) | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| EP1900732A4 (en) | 2005-06-24 | 2009-11-18 | Toyama Chemical Co Ltd | NEW NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| JP2009536667A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | ５ｈｔ受容体介在性の神経新生 |
| AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2009106534A1 (en) * | 2008-02-26 | 2009-09-03 | H. Lundbeck A/S | Novel heterocyclic carboxamides as m1 agonists |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2780015B1 (en) | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| AU2014240139A1 (en) * | 2013-03-15 | 2015-09-17 | Acadia Pharmaceuticals Inc. | Muscarinic agonists |
| CN103242230B (zh) * | 2013-05-02 | 2015-02-18 | 陕西步长高新制药有限公司 | 一种喹啉酮衍生物及其制备方法 |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| CA3150681A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| US11851426B2 (en) | 2019-10-11 | 2023-12-26 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN115073370B (zh) * | 2021-03-10 | 2024-12-17 | 成都硕德药业有限公司 | 新型烷基氨类化合物或盐、异构体、其制备方法及用途 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3365457A (en) * | 1964-05-08 | 1968-01-23 | Sterling Drug Inc | N [(1-, 2-, 3-indolyl)-lower alkyl]-1, 5-iminocycloalkane and-1, 5-iminocycloalkene derivatives |
| US3324137A (en) * | 1964-05-08 | 1967-06-06 | Sterling Drug Inc | N-[indolyl-lower-alkanoyl]-1, 5-iminocycloalkanes and -iminocycloalkenes |
| US3364457A (en) * | 1966-05-13 | 1968-01-16 | Navy Usa | Electrical adapter |
| JPS63290821A (ja) | 1987-05-25 | 1988-11-28 | Otsuka Pharmaceut Co Ltd | 抗不整脈剤 |
| JP2886570B2 (ja) * | 1989-09-29 | 1999-04-26 | エーザイ株式会社 | 縮合ヘテロ環を有する化合物 |
| CA2050264A1 (en) | 1990-08-30 | 1992-03-01 | Raymond Baker | Substituted pyrazine and its salts, compositions containing them and their use in medicine |
| US5093333A (en) | 1991-04-29 | 1992-03-03 | American Home Products Corporation | N-substituted-2-aminoquinolines useful for treating hypofunction of the cholinergic system |
| US5149815A (en) * | 1991-04-29 | 1992-09-22 | American Home Products Corporation | N-substituted-2-aminoquinolines |
| US5378698A (en) | 1991-10-21 | 1995-01-03 | Shionogi & Co., Ltd. | Benzothiazepine derivatives |
| JPH0673011A (ja) * | 1992-07-02 | 1994-03-15 | Sawai Seiyaku Kk | カルボスチリル誘導体および抗アレルギー剤 |
| US5457099A (en) | 1992-07-02 | 1995-10-10 | Sawai Pharmaceutical Co., Ltd. | Carbostyril derivatives and antiallergic agent |
| DE4228095A1 (de) | 1992-08-24 | 1994-03-03 | Asta Medica Ag | Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung |
| IL110298A (en) * | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| TW448161B (en) * | 1994-07-14 | 2001-08-01 | Otsuka Pharma Co Ltd | Cyclic amide derivatives |
| JPH0881442A (ja) * | 1994-07-14 | 1996-03-26 | Otsuka Pharmaceut Co Ltd | 環状アミド誘導体 |
| US5672709A (en) * | 1994-10-24 | 1997-09-30 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
| US5510478A (en) | 1994-11-30 | 1996-04-23 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| US5468875A (en) | 1994-12-22 | 1995-11-21 | American Home Products Corporation | 1-azabicycloheptane derivatives |
| WO1998007703A1 (en) * | 1996-08-22 | 1998-02-26 | Meiji Seika Kaisha, Ltd. | Quinoline derivatives and psychotropic agent |
| BR9909277A (pt) | 1998-03-31 | 2001-10-16 | Acadia Pharm Inc | Compostos com atividade em receptores muscarìnicos |
| US6699880B1 (en) | 1999-10-13 | 2004-03-02 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
| EP1464641B1 (en) | 1999-12-30 | 2008-05-14 | H. Lundbeck A/S | 4-Phenyl-piperazinyl, -piperidinyl and tetrahydropyridyl derivatives as dopamine D4 antagonists |
| US7166617B2 (en) | 2000-02-29 | 2007-01-23 | Mitsubishi Pharma Corporation | Cyclic amide derivatives |
| AR028385A1 (es) | 2000-04-28 | 2003-05-07 | Acadia Pharm Inc | Agonistas muscarinicos |
| WO2004089942A2 (en) * | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| US6951849B2 (en) * | 2001-10-02 | 2005-10-04 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| ES2251624T3 (es) | 2001-12-28 | 2006-05-01 | Acadia Pharmaceuticals Inc. | Analogos de la tetrahidroquinolina como los agonistas muscarinicos. |
| US7550459B2 (en) | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| NZ542690A (en) | 2003-03-28 | 2009-04-30 | Acadia Pharm Inc | Muscarinic M1 receptor agonists for pain management |
-
2004
- 2004-12-21 US US11/019,556 patent/US7550459B2/en not_active Expired - Fee Related
-
2005
- 2005-12-15 JP JP2007548300A patent/JP5114208B2/ja not_active Expired - Fee Related
- 2005-12-15 EP EP05854098A patent/EP1828176A1/en not_active Withdrawn
- 2005-12-15 CN CN201210222989.1A patent/CN102796095B/zh not_active Expired - Fee Related
- 2005-12-15 NZ NZ555994A patent/NZ555994A/en not_active IP Right Cessation
- 2005-12-15 MX MX2007007588A patent/MX2007007588A/es active IP Right Grant
- 2005-12-15 KR KR1020137019680A patent/KR20130095846A/ko not_active Ceased
- 2005-12-15 AU AU2005319426A patent/AU2005319426B2/en not_active Ceased
- 2005-12-15 CN CNA200580048487XA patent/CN101124222A/zh active Pending
- 2005-12-15 KR KR1020077015954A patent/KR101380794B1/ko not_active Expired - Fee Related
- 2005-12-15 BR BRPI0517485-6A patent/BRPI0517485A/pt not_active IP Right Cessation
- 2005-12-15 RU RU2007127849/04A patent/RU2434865C2/ru not_active IP Right Cessation
- 2005-12-15 WO PCT/US2005/045313 patent/WO2006068904A1/en not_active Ceased
- 2005-12-15 CA CA2591766A patent/CA2591766C/en not_active Expired - Fee Related
- 2005-12-20 TW TW102131073A patent/TW201414731A/zh unknown
- 2005-12-20 AR ARP050105365A patent/AR052343A1/es unknown
- 2005-12-20 TW TW094145345A patent/TWI433848B/zh active
-
2007
- 2007-06-19 IL IL184065A patent/IL184065A/en not_active IP Right Cessation
- 2007-06-21 NO NO20073183A patent/NO20073183L/no not_active Application Discontinuation
-
2009
- 2009-05-27 US US12/473,220 patent/US8680115B2/en not_active Expired - Fee Related
-
2012
- 2012-05-21 IL IL219920A patent/IL219920A/en not_active IP Right Cessation
-
2014
- 2014-02-05 US US14/173,627 patent/US9522906B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008524328A5 (enExample) | ||
| RU2007127849A (ru) | Аналоги тетрагидрохинолина в качестве мускариновых агонистов | |
| JP2008133297A5 (enExample) | ||
| ECSP088499A (es) | Nuevos compuestos de 2-amino-imidazol-4-ona y su uso en la fabricación de un medicamento para uso en el tratamiento de alteración cognitiva, enfermedad de alzheimer, neurodegeneración y demencia | |
| JP2008526999A5 (enExample) | ||
| AR070395A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il- amina | |
| DOP2005000040A (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos | |
| JP2013540755A5 (enExample) | ||
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| JP2014509647A5 (enExample) | ||
| JP2011517453A5 (enExample) | ||
| NZ590951A (en) | Cyclic nucleotide phosphodiesterases PDE10 inhibitors for treating neurological disorders | |
| MX2009011812A (es) | Aminopirimidinas utiles como inhibidores de cinasa. | |
| IL189191A0 (en) | Thiazolyl piperidine derivatives useful as h3 receptor modulators | |
| MX2009003874A (es) | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. | |
| DE602007004851D1 (de) | A2a-adenosin-rezeptor-antagonisten | |
| CO6251201A2 (es) | Composiciones y metodos para el tratamiento de3 enfermedades y desordenes oftalmicos | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| UY30377A1 (es) | Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa | |
| WO2009143178A3 (en) | Pde10 inhibitors and related compositions and methods | |
| PE20071090A1 (es) | 5-pirazolpiperidinas-(sustituidas) | |
| JP2020520925A (ja) | 化合物、組成物および方法 | |
| JP2015502371A5 (enExample) | ||
| JP2008525513A5 (enExample) | ||
| IL205045A (en) | Piperidinyl and piperazine derivatives, preparations containing them and their uses |